Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 835-841

  Tahara, Minoru ^a   Pergolizzi, Robert G ^a   Kobayashi, Hiroyasu ^a   Krause, Anja ^a   Luettich, Karsta ^a   Lesser, Martin L ^b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b N Shore Long Isl Jewish Res Inst ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; LENTIVIRUS VECTOR; MESSENGER RNA PRECURSOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; HELPER CELL; HYPERIMMUNOGLOBULINEMIA M; KNOCKOUT MOUSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANS SPLICING; WILD TYPE; X CHROMOSOME LINKED DISORDER;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC DISEASES, X-LINKED; GENETIC ENGINEERING; HEMOCYANIN; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LENTIVIRUS; LUNG; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, KNOCKOUT; MUTATION; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

ANIMALIA; LENTIVIRUS; PNEUMOCYSTIS CARINII;

EID: 4043179784     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1086     Document Type: Article

References (48)

1. Callard, R.E., Armitage, R.J., Fanslow, W.C. & Spriggs, M.K. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14, 559-564 (1993).
2. Kroczek, R.A. et al. Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGM1)". Immunol. Rev. 138, 39-59 (1994).
3. Di Santo, J.P., Bonnefoy, J.Y., Gauchat, J.F., Fischer, A. & de Saint, B.C. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 361, 541-543 (1993).
4. Korthauer, U. et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361, 539-541 (1993).
5. + T cells. J. Immunol. 151, 2497-2510 (1993).
6. Stout, R.D., Suttles, J., Xu, J., Grewal, I.S. & Flavell, R.A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156, 8-11 (1996).
7. Grewal, I.S. & Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
8. Straw, A.D., MacDonald, A.S., Denkers, E.Y. & Pearce, E.J. CD154 plays a central role in regulating dendritic cell activation during infections that induce Th1 or Th2 responses. J. Immunol. 170, 727-734 (2003).
9. Gennery, A.R. et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 103, 1152-1157 (2004).
10. Levy, J. et al. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131, 47-54 (1997).
11. Hadzic, N. et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N. Engl. J. Med. 342, 320-324 (2000).
12. Thomas, C. et al. Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. N. Engl. J. Med. 333, 426-429 (1995).
13. Brown, M.P. et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 4, 1253-1260 (1998).
14. Sacco, M.G. et al. Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 7, 1299-1306 (2000).
15. Sullenger, B.A. Targeted genetic repair: an emerging approach to genetic therapy. J. Clin. Invest. 112, 310-311 (2003).
16. Puttaraju, M., Jamison, S.F., Mansfield, S.G., Garcia-Blanco, M.A. & Mitchell, L.G. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat. Biotechnol. 17, 246-252 (1999).
17. Garcia-Blanco, M.A., Puttaraju, M., Mansfield, S.G. & Mitchell, L.G. Spliceosome-mediated RNA trans-splicing in gene therapy and genomics. Gene Ther. Regul. 1, 141-163 (2000).
18. Liu, X. et al. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat. Biotechnol. 20, 47-52 (2002).
19. Mansfield, S.G. et al. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther. 7, 1885-1895 (2000).
20. Puttaraju, M., Di Pasquale, J., Baker, C.C., Mitchell, L.G. & Garcia-Blanco, M.A. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. Mol. Ther. 4, 105-114 (2001).
21. Chao, H. et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. 9, 1015-1019 (2003).
22. Garcia-Blanco, M.A. Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J. Clin. Invest. 112, 474-480 (2003).
23. Bonen, L. Trans-splicing of pre-mRNA in plants, animals, and protists. FASEB J. 7, 40-46 (1993).
24. Caudevilla, C. et al. Natural trans-splicing in carnitine octanoyltransferase pre-mRNAs in rat liver. Proc. Natl. Acad. Sci. USA 95, 12185-12190 (1998).
25. Xu, J. et al. Mice deficient for the CD40 ligand. Immunity. 1, 423-431 (1994).
26. Testi, R., D'Ambrosio, D., De Maria, R. & Santoni, A. The CD69 receptor: a multi-purpose cell-surface trigger for hematopoietic cells. Immunol. Today 15, 479-483 (1994).
27. Kolls, J.K., Beck, J.M., Nelson, S., Summer, W.R. & Shellito, J. Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am. J. Respir. Cell Mol. Biol. 8, 370-376 (1993).
28. + T cells. J. Immunol. 162, 2890-2894 (1999).
29. Logan, A.C., Lutzko, C. & Kohn, D.B. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr. Opin. Biotechnol. 13, 429-436 (2002).
30. Baumgartner, R. et al. Evidence for the requirement of T cell costimulation in the pathogenesis of natural Pneumocystis carinii pulmonary infection. Microb. Pathog. 33, 193-201 (2002).
31. Campbell, K.A. et al. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4, 283-289 (1996).
32. MacDonald, A.S. et al. Impaired Th2 development and increased mortality during Schistosoma mansoni infection in the absence of CD40/CD154 interaction. J. Immunol. 168, 4643-4649 (2002).
33. Netea, M.G., Meer, J.W., Verschueren, I. & Kullberg, B.J. CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur. J. Immunol. 32, 1455-1463 (2002).
34. Soong, L. et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4, 263-273 (1996).
35. Stephens, J., Cosyns, M., Jones, M. & Hayward, A. Liverand bile duct pathology following Cryptosporidium parvum infection of immunodeficient mice. Hepatology 30, 27-35 (1999).
36. Thomsen, A.R., Nansen, A., Christensen, J.P., Andreasen, S.O. & Marker, O. CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. J. Immunol. 161, 4583-4590 (1998).
37. Merali, S., Chin, K., Grady, R.W., Weissberger, L. & Clarkson, A.B. Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob. Agents Chemother. 39, 1442-1444 (1995).
38. + T cell-independent vaccination against Pneumocystis carinii in mice. J. Clin. Invest. 108, 1469-1474 (2001).
39. Pergolizzi, R.G. et al. In vivo trans-splicing of 5′ and 3′ segments of pre-mRNA directed by corresponding DNA sequences delivered by gene transfer. Mol. Ther. 8, 999-1008 (2003).
40. Armitage, R.J. et al. Molecular and biological characterization of a murine ligand for CD40. Nature 357, 80-82 (1992).
41. Field, J. et al. Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Mol. Cell. Biol. 8, 2159-2165 (1988).
42. Xu, K., Ma, H., McCown, T.J., Verma, I.M. & Kafri, T. Generation of a stable cell line producing high-liter self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104 (2001).
43. Naldihi, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996).
44. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
45. Szilvassy, S.J., Lansdorp, P.M., Humphries, R.K., Eaves, A.C. & Eaves, C.J. Isolation in a single step of a highly enriched murine hematopoietic stem cell population with competitive long-term repopulating ability. Blood 74, 930-939 (1989).
46. Vigna, E. et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther. 5, 252-261 (2002).
47. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M. & Naldini, L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25, 217-222 (2000).
48. + T cells. Nat. Med. 6, 1154-1159 (2000).